Repros Therapeutics Inc (RPRX)

[io_io]

3. Cost effects 3 trials.

Duh..

Yes that's why I kept it short. I presume you meant "Phase 3 trials' size". Perhaps you are drinking some excellent vino tonight ?

4. Clinical effect vs. stat sig

This is a point that David at BSR has been pounding the drums on. Running a 2000 patient trial to detect a microscopic improvement in some clinical condiction is just not impressive.

Yes, but not mentioned in the discussions here on "trial design under-powering" - and it mirrors the Proellex situation (because of Lupron being avalable and cheap).

5. Bigger trials might be bad because safety issues could outweight benifit.

Sorry, unless I misunderstand you, you lost your mind on this one.

No, you did. Designing for bigger trials means designing for smaller clinical benefit. Not good when there is a safety issue affecting risk-reward balance (ask FDA).